| Literature DB >> 25834433 |
Karmani Murugan1, Yahya E Choonara1, Pradeep Kumar1, Divya Bijukumar1, Lisa C du Toit1, Viness Pillay1.
Abstract
Cellular internalization and trans-barrier transport of nanoparticles can be manipulated on the basis of the physicochemical and mechanical characteristics of nanoparticles. Research has shown that these factors significantly influence the uptake of nanoparticles. Dictating these characteristics allows for the control of the rate and extent of cellular uptake, as well as delivering the drug-loaded nanosystem intra-cellularly, which is imperative for drugs that require a specific cellular level to exert their effects. Additionally, physicochemical characteristics of the nanoparticles should be optimal for the nanosystem to bypass the natural restricting phenomena of the body and act therapeutically at the targeted site. The factors at the focal point of emerging smart nanomedicines include nanoparticle size, surface charge, shape, hydrophobicity, surface chemistry, and even protein and ligand conjugates. Hence, this review discusses the mechanism of internalization of nanoparticles and ideal nanoparticle characteristics that allow them to evade the biological barriers in order to achieve optimal cellular uptake in different organ systems. Identifying these parameters assists with the progression of nanomedicine as an outstanding vector of pharmaceuticals.Entities:
Keywords: cellular uptake; charge; nanoparticles; shape; size; transport mechanisms
Mesh:
Substances:
Year: 2015 PMID: 25834433 PMCID: PMC4370919 DOI: 10.2147/IJN.S75615
Source DB: PubMed Journal: Int J Nanomedicine ISSN: 1176-9114
Figure 1The transport mechanisms of a typical biological barrier.
Notes: (A) Cellular internalization of nanoparticle into cell via endocytosis; (B) transcellular transport of nanoparticles through cell; (C) paracellular transport of nanoparticle between cells through the tight junction; and (D) receptor-mediated transcytosis.
Key terms
| Term | Definition |
|---|---|
| Cellular internalization | Process by which biological and foreign matter is taken up by cells. |
| Endocytosis | Energy or enzyme-dependent mechanism of cellular internalization. |
| Trans-barrier | Refers to transport of nano- and micro-substances through cells from extracellular fluid through the apical and basolateral membrane. |
| Opsonization | Biological phenomenon whereby opsonin molecules adsorb onto the surface of foreign particles to enhance RES recognition and phagocytosis. |
| PRINT particles | Particles fabricated using a lithographic technique of PRINT to produce monodisperse, shape-controlled particles. |
Abbreviations: PRINT, particle replication in non-wetting templates; RES, reticuloendothelial system.
Figure 2Mechanisms of endocytosis subdivided into categories of cell uptake.
Figure 3Mechanism of clathrin-mediated endocytosis of nanoparticles.
Figure 4The mechanisms of caveolin-mediated endocytosis, macropinocytosis, and phagocytosis.
Figure 5Representation of the internalization potential dependent on particle size.
Note: The larger surface area of the nanoparticle allows for increased surface contact with the cell membrane for higher internalization rates as described in the investigation of Nicolete et al.41
Figure 6Particle internalization based on orientation to the membrane.
Notes: (A) Schematic showing the angle between the long axis of the particle and the bilayer normal; (B) minimum driving forces required to guide the ellipsoid with different initial orientations of the long axis through the lipid bilayer; (C) time evolution of particle orientations during the ellipsoid penetration processes with different initial orientations. Reprinted by permission from Macmillan Publishers Ltd: Nature Nanotechnology. Yang K, Ma YQ. Computer simulation of the translocation of nanoparticles with different shapes across a lipid bilayer. Nat Nanotechnol. 2010;5(8):579–583. Copyright © 2010.56
Figure 7(1) Pathway of uncoated hydrophobic nanoparticle; (2) pathway of coated hydrophilic nanoparticle.
Notes: (1) (A) Nanoparticle in blood circulation; (B) opsonins recognize nanoparticle as a foreign body due to the hydrophobic surface; (C) opsonization of nanoparticle; (D) and (E) phagocytosis by phagocyte and elimination of nanoparticle. (2) (A) Hydrophilic polymer-coated nanoparticle in blood circulation; (B) steric hindrance maintains repulsive forces between opsonins and nanoparticle; (C) nanoparticle continues to circulate until target site reached; (D) and (E) endocytosis by target cell.
Figure 8Stimulating endocytosis through CPP and antibody conjugation of nanoparticles.
Abbreviation: CPP, cell-penetrating protein or peptide.
Overview of biological barriers and nanoparticle advances to overcome physiological limitations
| Organ system | Barriers to internalization | Physicochemical nanoparticle modification | (Trans)-epithelial transport mechanisms | Reference |
|---|---|---|---|---|
| Skin | Insoluble corneocytes and tight junctions in viable epidermis | • Chemical enhancers (oleic acid, ethanol, PEG) to surface coat | Pores, trans/intercellular, follicular penetration | |
| • 215.2 nm anionic quercetin-loaded lipid NPs | Intercellular permeation | |||
| Pilosebaceous (10–70 mm) and sweat glands (60–80 mm) | • <10 nm metal maghemite NPs | Lipidic matrix, follicular penetration | ||
| Intercellular lipidic matrix | • Hydrophilic 40 nm irregular, spherical PEG-b-copolymer NPs | Follicular penetration | ||
| • 18 nm hydrophobic cationic/neutral 18 nm ellipsoid/spherical quantum dots | Pores, follicular penetration | |||
| Blood | Complement system, phagocytosis | • Heparin-complexed cerium oxide NPs for monocyte drug delivery | ||
| White blood cells | • Cell membranes contain regions of +ve and −ve charge, NPs of either charge can be internalized | |||
| Ocular | Blood–aqueous barrier | • 180 nm anionic sparfloxacin-loaded PLGA NPs | Nasolacrimal drainage system | |
| Blood–retinal barrier | • 3.46 μm surfactant-complexed multilamellar acetazolamide niosomes | |||
| Precorneal tear film (3–10 μm) | • 161 nm PEG-coated poly-ε-caprolactone nanocapsules | Transcytosis | ||
| Spinal cord | BSCB | • 2–5 nm cerium oxide NPs | ||
| Astrocytic foot processes | • Ideal properties for penetrating BSCB/astrocytic foot processes | |||
| • NP size (<50 nm), cationic, hydrophilic, CPP-complexed | ||||
| Brain | BBB, blood–cerebrospinal fluid barrier | • Hydrophilic PEG-coated poly hexadecyl cyanoacrylate | Caveolae-mediated endocytosis | |
| • Chemical/biological/physical modulators for opening BBB | Trans/paracellular | |||
| Enzymatic BBB | • MAb 5C6, to CR3 receptor-a β2-integrin present on microglia | Receptor-mediated transcytosis | ||
| • RMP-7 (bradykinin analog)-coated 50 nm NPs | ||||
| • Polyether-copolyester dendrimers | Clathrin/caveolae-mediated uptake | |||
| High transendothelial electrical resistance of 1,500–2,000 V/cm2 | • Cationization of antibodies to undergo active transport | Absorptive mediated transcytosis | ||
| • Anionic, 90 nm transferrin (Tf)-conjugated polymersomes | Tf receptor-mediated transcytosis | |||
| • Anionic, ≤200 nm SLNs | ||||
| • Cationic, 190–210 nm nano-lipid emulsion | Caveolae-mediated end/macropinocytosis | |||
| Brain extracellular space of 38–64 nm | • Anionic, 154 nm PLGA NPs via inner ear administration | Pinocytosis | ||
| • 80 nm TiO2 NPs administered through intranasal instillation | Transcytosis | |||
| Liver | Tight junctions, 5–10 μm wide BVs | • Filo-shaped micelles with high aspect ratios and cylindrical shape | Clathrin/caveolae-mediated endocytosis | |
| • 20 nm carboxylated polystyrene | ||||
| • 47.2 nm cationic chitosan NPs of irregular shape modified with glycyrrhizin complexation | Receptor-mediated endocytosis | |||
| Phagocytic properties of juxtaposed Kupffer cells | • CPPs conjugated on <90 nm cationic NPs to target AGP receptors on hepatocytes for direct drug delivery | Receptor-mediated endocytosis | ||
| • Saturating Kupffer cells with excess of drug-loaded NPs | ||||
| • Particles of 1–3 μm evade ruffled surface of Kupffer cells | ||||
| Protective mucin layer | • Neutral, hydrophobic NPs <200 nm | |||
| Oral cavity | Non-keratinized epithelia, saliva mucus, membrane-coating granules of buccal mucosa | • NPs entrapped within solid lozenges, chewing gum, flexible adhesive patches, and viscous liquids to coat mucosa | ||
| GIT | Tight junction barriers, cell composition | • Coating drug-loaded NPs with bacterial invasive ligands to target M cell surface components | Receptor-mediated endocytosis | |
| Low pH gradients | • pH-sensitive cationic 343 nm trimethylchitosan and 212 nm PLGA-PEG mannose NPs | Receptor-mediated endocytosis | ||
| Thick, anionic mucus layer | • 154 nm cationic poly-6-cationic amphiphilic cyclodextrin–DNA complex internalized by intestinal epithelial cells | Macropinocytosis | ||
| Macrophages | • Hydrophobic, neutral aminated NPs | Transcytosis | ||
| Lungs | Alveolar–capillary barrier, complex tight junctions | • 15–100 nm gold NPs | Transcytosis | |
| • Commercial multi-walled carbon-NTs disrupt tight junctions | Paracellular | |||
| • Hydrophilic, surfactant-coated, enzymatic 20 nm PEI-PLGA NPs in 1.6 μm microgel | ||||
| • Discoidal-shaped NPs | ||||
| Alveolar lining fluid | • 200 nm NPs complexed with Fc portion of IgG | Receptor-mediated endocytosis | ||
| Macrophages | • 235 nm protein-based NPs (serum albumin and transferrin) | Receptor-mediated transcytosis | ||
| Kidney | 200–300 nm thick glycocalyx layer | • 78–100 nm spherical PLGA NPs | Caveolae-mediated endocytosis | |
| Phagocytic mesangial cells | • Albumin/streptavidin as ligands targeting renal tubular cells | Receptor-mediated endocytosis | ||
| Cationic decomplexation | • Anionic derivatives carboxylated, co-dimethyl maleic acid, acetylated low-molecular weight chitosan, or PVP as NP coating | Receptor-mediated endocytosis |
Abbreviations: AGP, alpha 1-acid glycoprotein; BBB, blood–brain barrier; BSCB, blood–spinal cord barrier; BV, blood vessel; CPPs, cell-penetrating proteins or peptides; GIT, gastrointestinal tract; NP, nanoparticle; NT, nanotube; PEG, poly(ethylene glycol); PEI, polyethylenimine; PLGA, poly(lactic-co-glycolic acid); PVP, poly-vinyl pyyrolidone; SLN, solid lipid nanoparticle.